BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28453751)

  • 1. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
    Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma.
    Ung TH; Ney DE; Damek D; Rusthoven CG; Youssef AS; Lillehei KO; Ormond DR
    Neurosurgery; 2019 Mar; 84(3):687-695. PubMed ID: 29618103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Assessment in Neuro-Oncology Clinical Trials.
    Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
    J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Criteria in Neuro-oncology.
    Nowosielski M; Wen PY
    Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
    Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
    Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
    Huang RY; Wen PY
    Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
    Arvold ND; Armstrong TS; Warren KE; Chang SM; DeAngelis LM; Blakeley J; Chamberlain MC; Dunbar E; Loong HH; Macdonald DR; Reardon DA; Vogelbaum MA; Yuan Y; Weller M; van den Bent M; Wen PY
    Neuro Oncol; 2018 Jun; 20(7):897-906. PubMed ID: 29788429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
    Sharma M; Juthani RG; Vogelbaum MA
    Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Brain Tumor Response: RANO and Its Offspring.
    Eisele SC; Wen PY; Lee EQ
    Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
    J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
    Youssef G; Wen PY
    Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Ellingson BM; Brown MS; Boxerman JL; Gerstner ER; Kaufmann TJ; Cole PE; Bacha JA; Leung D; Barone A; Colman H; van den Bent MJ; Wen PY; Alfred Yung WK; Cloughesy TF; Goldin JG
    Neuro Oncol; 2021 Feb; 23(2):189-198. PubMed ID: 33130879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
    Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
    Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early imaging marker of progressing glioblastoma: a window of opportunity.
    Gatson NTN; Bross SP; Odia Y; Mongelluzzo GJ; Hu Y; Lockard L; Manikowski JJ; Mahadevan A; Kazmi SAJ; Lacroix M; Conger AR; Vadakara J; Nayak L; Chi TL; Mehta MP; Puduvalli VK
    J Neurooncol; 2020 Jul; 148(3):629-640. PubMed ID: 32602020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
    Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
    AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
    Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
    Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
    Wen PY; Cloughesy TF; Ellingson BM; Reardon DA; Fine HA; Abrey L; Ballman K; Bendszuz M; Buckner J; Chang SM; Prados MD; Pope WB; Gregory Sorensen A; van den Bent M; Yung WK
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii36-47. PubMed ID: 25313237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.
    Leao DJ; Craig PG; Godoy LF; Leite CC; Policeni B
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):10-20. PubMed ID: 31857322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.